Clinical Trials Directory

Trials / Unknown

UnknownNCT02557607

Quantification of Cerebral Blood Flow by Arterial Spin Labeling in Vasospasm in Subarachnoid Haemorrhage

Quantification of Cerebral Blood Flow by Arterial Spin Labeling in the Screening and Monitoring of Vasospasm in Subarachnoid Haemorrhage

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
50 (estimated)
Sponsor
University Hospital, Angers · Other Government
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

A technique of MRI infusion -l'Arterial Spin Labeling-, non-invasive and non-irradiating, repeatable over time, appears promising in the field. This sequence allows for routine, generate perfusion maps relating to the entire brain volume

Detailed description

The subarachnoid hemorrhage (SAH) is a relatively severe disease whose prognosis is particularly related to the early onset of arterial vasospasm, maximum between the 5th and 14th day after SAH. Many obstacles make it difficult screening and monitoring of such complication. The challenge is to be able to demonstrate a reduction in regional cerebral blood flow before the onset of irreversible parenchymal sequelae, responsible for the majority of long-term morbidity among survivors. In clinical routine, screening vasospasm is achieved by Doppler intracranial arteries (DTC). However, its sensitivity is poor with regard to the middle and anterior cerebral arteries. The gold standard for diagnosis is cerebral arteriography. However, vasospasm in arteriography or trans-cranial Doppler does not prejudice the appearance of a delayed ischemic deficit. A technique of MRI infusion -l'Arterial Spin Labeling-, non-invasive and non-irradiating, repeatable over time, appears promising in the field. This sequence allows for routine, generate perfusion maps relating to the entire brain volume

Conditions

Interventions

TypeNameDescription
DEVICEMRIAn analysis of the three sessions MRI performed systematically within the first 14 days of the start of symptoms revealing the HSA will be

Timeline

Start date
2014-12-01
Primary completion
2017-12-01
Completion
2018-01-01
First posted
2015-09-23
Last updated
2015-09-23

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT02557607. Inclusion in this directory is not an endorsement.